Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Adaptimmune Therapeutics plc. (3/2/17). "Press Release: Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference". Philadeliphia, PA & Oxford.

Region Region Philadelphia, PA
  Country United States (USA)
Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 Cowen & Company LLC
Products Product Cowen & Co. Annual Health Care Conference 2017 Boston
  Product 2 SPEAR™ T-cell therapy
Index term Index term Adaptimmune–Cowen: investor conference, 201703 supply service Adaptimmune presents at Cowen & Co Annual Health Care Conference 2017
Persons Person Noble, James (Adaptimmune 201909– Non-Executive Director before CEO before MediGene + Avidex)
  Person 2 Roberts, Will (G1 Therapeutics 202211 VP IR + Corp Communications before Adaptimmune 201602 VP IR)

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday March 7, 2017 at 10:40-11:10 AM EST (3:40-4:10 PM GMT). The conference is being held at the Boston Marriott Copley Plaza. Adaptimmune’s presentation will be webcast live for investors through the investor section of and available for a period of 30 days following the conference.

About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit

Adaptimmune Contacts

Investor Relations
Will Roberts
T: (215) 825-9306

Juli P. Miller, Ph.D.
T: (215) 825-9310

Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249

Adaptimmune Therapeutics plc

Record changed: 2023-06-05


Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Adaptimmune (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top